Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ATOSSA THERAPEUTICS, INC. (ATOS)

Atossa Therapeutics Q3 2026 net loss narrows to $5.6 million from $8.7 million

Positive Impact 3 of 5 earnings

Atossa Therapeutics reported a third-quarter 2026 net loss of $5.6 million, or $0.56 per share, compared with $8.7 million, or $1.01 per share, a year earlier. Operating expenses fell to $5.9 million from $9.3 million, and the filing reports no revenue. Cash and cash equivalents were $20.6 million at September 30, 2026, down from $41.3 million at December 31, 2025, and the company also disclosed a contingent value rights agreement tied to a possible future priority review voucher sale.

Key points

  • Q3 2026 net loss was $5.6 million ($0.56 per share), versus $8.7 million ($1.01 per share) in Q3 2025.
  • Nine-month 2026 net loss was $23.7 million ($2.58 per share), versus $23.8 million ($2.76 per share) a year earlier.
  • Cash and cash equivalents were $20.6 million at September 30, 2026, versus $41.3 million at December 31, 2025.
  • Under the CVR agreement dated October 8, 2026, holders are entitled to 25% of net proceeds from the first qualifying FDA priority review voucher sale, capped at $50 million; no voucher has been awarded.

The filing

CompanyATOSSA THERAPEUTICS, INC. (ATOS)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:15 AM ET
Accession number0001193125-26-454486

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:25 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.